Psoriasis is a chronic inflammatory T cell-mediated skin disease, affecting about 2% of Hungarian population. Genetic predisposition as well as environmental triggering factors, and innate immune processes play a role in its etiology. Treatment of psoriasis during the initial stages and first years of disease tend to be conservative and frequently based on topical agents. The aim of this study was to investigate and to describe the efficacy and safety of Dr Michaels® (Soratinex®) skin-care products for the topical treatment of stable chronic plaque psoriasis in a Hungarian population. Two-hundred-and-eight-six (120 female/166 male) patients, aged 10-80 years old (mean age 43 years) with mild to moderate plaque psoriasis had participated in the study. The products, including cleansing gel containing a coal tar solution, herbal oils and emulsifiers, were used twice daily and in the same manner for all the skin lesions. The study period was eight weeks. Assessment, using the Psoriasis Activity Severity Index (PASI) scores and photographic analysis, was done 2 weeks before treatment, at time 0, and after 2, 4, 6 and 8 weeks. Patient’s improvement was determined by the percentage reduction of the PASI scores. Side effects and tolerability were also evaluated. After 8 weeks treatment course, 46 patients had a moderate improvement, with the regression of 25-50% of skin lesions; 77 patients showed a good improvement, with the resolution of 51-75% of lesions. Another 115 patients had an outstanding improvement, with the regression of 76-98.9% of lesions. Only 13 patients did not achieve an improvement of psoriasis. Fifteen patients experienced folliculitis, which resolved after cessation of treatment. Seven patients worsened and discontinued treatment. Thirteen patients dropped out because of non-compliance. Our investigation demonstrates that Dr Michaels® (Soratinex®) products, an Australian treatment, can be used successfully in the treatment of stable chronic plaque psoriasis.

2nd Medical Faculty Charles University Bulovka Hospital Institute of Clinical and Experimental Medicine Prague Czech Republic

Centro Studi per la Ricerca Multidisciplinare e Rigenerativa Università Degli Studi G Marconi Rome Italy

Chair of Dermatology University of Rome G Marconi Rome Italy

Department Medicinal Information and Non interventional studies Bulgarian Drug Agency Sofia Bulgaria

Department of Dermatology and Allergology Academic Teaching Hospital Dresden Friedrichstadt Dresden Germany

Department of Dermatology and Cutaneous Surgery Department of Psychiatry and Behavioral Sciences Institute for Bioethics and Health Policy University of Miami Miller School of Medicine Miami FL USA

Department of Dermatology and Venereology Medical University of Plovdiv Medical faculty Plovdiv Bulgaria

Department of Nuclear Physics Sub nuclear and Radiation G Marconi University Rome Italy

Dermatological Department University of Pisa Pisa Italy

Medical Institute of Ministry of Interior Department of Dermatology Venereology and Dermatologic Surgery Sofia Bulgaria

Onkoderma Policlinic for dermatology and dermatologic surgery Sofia Bulgaria

PRO SANUM Ltd Sanatorium of Prof Novotný Štěpánská Prague 1 Czech Republic

Psoriasis and Skin Clinic Melbourne Australia

University B 1 S Group of Institutions Punjab Technical University Punjab India

000      

00000naa a2200000 a 4500

001      

bmc19001373

003      

CZ-PrNML

005      

20190308132109.0

007      

ta

008      

190107s2016 it f 000 0|eng||

009      

AR

035    __

$a (PubMed)27498657

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a it

100    1_

$a Hercogová, J $u 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.

245    10

$a Dr Michaels® (Soratinex®) product for the topical treatment of psoriasis: a Hungarian/Czech and Slovak study / $c J. Hercogová, M. Fioranelli, S. Gianfaldoni, AA. Chokoeva, G. Tchernev, U. Wollina, M. Tirant, F. Novotny, MG. Roccia, GK. Maximov, K. França, T. Lotti,

520    9_

$a Psoriasis is a chronic inflammatory T cell-mediated skin disease, affecting about 2% of Hungarian population. Genetic predisposition as well as environmental triggering factors, and innate immune processes play a role in its etiology. Treatment of psoriasis during the initial stages and first years of disease tend to be conservative and frequently based on topical agents. The aim of this study was to investigate and to describe the efficacy and safety of Dr Michaels® (Soratinex®) skin-care products for the topical treatment of stable chronic plaque psoriasis in a Hungarian population. Two-hundred-and-eight-six (120 female/166 male) patients, aged 10-80 years old (mean age 43 years) with mild to moderate plaque psoriasis had participated in the study. The products, including cleansing gel containing a coal tar solution, herbal oils and emulsifiers, were used twice daily and in the same manner for all the skin lesions. The study period was eight weeks. Assessment, using the Psoriasis Activity Severity Index (PASI) scores and photographic analysis, was done 2 weeks before treatment, at time 0, and after 2, 4, 6 and 8 weeks. Patient’s improvement was determined by the percentage reduction of the PASI scores. Side effects and tolerability were also evaluated. After 8 weeks treatment course, 46 patients had a moderate improvement, with the regression of 25-50% of skin lesions; 77 patients showed a good improvement, with the resolution of 51-75% of lesions. Another 115 patients had an outstanding improvement, with the regression of 76-98.9% of lesions. Only 13 patients did not achieve an improvement of psoriasis. Fifteen patients experienced folliculitis, which resolved after cessation of treatment. Seven patients worsened and discontinued treatment. Thirteen patients dropped out because of non-compliance. Our investigation demonstrates that Dr Michaels® (Soratinex®) products, an Australian treatment, can be used successfully in the treatment of stable chronic plaque psoriasis.

650    _2

$a aplikace lokální $7 D000287

650    _2

$a mladiství $7 D000293

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a dítě $7 D002648

650    _2

$a dehet uhelný $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D003033

650    _2

$a Česká republika $7 D018153

650    _2

$a emulgační látky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D045703

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a Maďarsko $7 D006814

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a oleje rostlin $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D010938

650    _2

$a psoriáza $x farmakoterapie $x patologie $7 D011565

650    _2

$a péče o kůži $x škodlivé účinky $x metody $7 D017592

650    _2

$a Slovenská republika $7 D018154

650    _2

$a výsledek terapie $7 D016896

650    _2

$a mladý dospělý $7 D055815

655    _2

$a klinické zkoušky $7 D016430

655    _2

$a časopisecké články $7 D016428

700    1_

$a Fioranelli, M $u Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.

700    1_

$a Gianfaldoni, S $u Dermatological Department University of Pisa, Pisa, Italy.

700    1_

$a Chokoeva, A A $u Onkoderma - Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria.

700    1_

$a Tchernev, G $u Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.

700    1_

$a Wollina, U $u Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.

700    1_

$a Tirant, M $u Psoriasis and Skin Clinic, Melbourne, Australia.

700    1_

$a Novotny, F $u PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic.

700    1_

$a Roccia, M G $u University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India.

700    1_

$a Maximov, G K $u Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency Sofia, Bulgaria.

700    1_

$a França, K $u Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy.

700    1_

$a Lotti, T $u Chair of Dermatology, University of Rome G. Marconi Rome, Italy.

773    0_

$w MED00008336 $t Journal of biological regulators and homeostatic agents $x 0393-974X $g Roč. 30, č. 2 Suppl 3 (2016), s. 43-7

856    41

$u https://pubmed.ncbi.nlm.nih.gov/27498657 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20190107 $b ABA008

991    __

$a 20190308132425 $b ABA008

999    __

$a ok $b bmc $g 1364070 $s 1039496

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2016 $b 30 $c 2 Suppl 3 $d 43-7 $i 0393-974X $m Journal of Biological Regulators & Homeostatic Agents $n J Biol Regul Homeost Agents $x MED00008336

LZP    __

$a Pubmed-20190107